Skip to main content
Helmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logo
Stefanie Winkler

Type 1 Diabetes Immunology

Our main research interest focusses on understanding the role of regulatory T cells in the development and progression of autoimmune diseases such as Type 1 Diabetes. To do so, we combine the analysis of human immune cells from different disease stages with mechanistic studies in murine and humanized in vivo models. We focus on the following research topics: We dissect key molecular mechanisms underlying regulatory T cell impairments in autoimmunity and investigate the heterogeneity, plasticity and functional specialization of regulatory T cells in metabolic tissues of diabetes. Our studies have the overarching goal to facilitate the future context-specific manipulation of regulatory T cells in (autoimmune) diabetes.

Our main research interest focusses on understanding the role of regulatory T cells in the development and progression of autoimmune diseases such as Type 1 Diabetes. To do so, we combine the analysis of human immune cells from different disease stages with mechanistic studies in murine and humanized in vivo models. We focus on the following research topics: We dissect key molecular mechanisms underlying regulatory T cell impairments in autoimmunity and investigate the heterogeneity, plasticity and functional specialization of regulatory T cells in metabolic tissues of diabetes. Our studies have the overarching goal to facilitate the future context-specific manipulation of regulatory T cells in (autoimmune) diabetes.

Follow us on TwitterWe are hiring!

On This Page

Explore Research at TDI

About our Research

Type 1 Diabetes is an autoimmune disease with a dramatically increasing incidence, particularly in childhood. It results from a breakdown in immune tolerance that causes the autoimmune-mediated destruction of the insulin-producing beta cells in the pancreas and a subsequent loss of glycemic control. We aim to advance our understanding of the immune mechanisms underlying Type 1 Diabetes development. Our overall vision is to contribute to the development of immune therapies that can decelerate or even halt autoimmune progression and prevent diabetes complications.

Giovanni Cancemi - stock.adobe.com

Our Main Research Topics

See all
Martin Scherm / BioRender

Autoantigen-specific T cell and Treg responses

Helmholtz Munich | ©BioRender

Personalized immunological models of human disease

Helmholtz Munich | ©BioRender

Treg impairments during islet autoimmunity

Martin Scherm / BioRender

Next-generation miRNA targeting strategies

Helmholtz Munich | ©BioRender

Novel drug candidates to control T1D autoimmunity

Martin Scherm / BioRender

Immune-metabolic crosstalk in target tissues of diabetes

Exercise and Muscle Regulation: Implications for Diabetes and Obesity

How do our muscles respond at the molecular level to exercise? Researchers at Helmholtz Munich and the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE) have unraveled the cellular basis and signaling pathways responsible for the positive…

read more

Advancing Stem Cell-Based Therapy for Type 1 Diabetes

With a 2.25 million US dollar grant provided by the Juvenile Diabetes Research Foundation (JDRF), Prof. Matthias Hebrok, Prof. Heiko Lickert, and Prof. Carolin Daniel from the Helmholtz Munich Diabetes Center, and Prof. Eckhard Wolf from Ludwig…

read more

Four Helmholtz Munich scientists participate in new DFG CRC/TRR

The German Research Foundation funds a new Collaborative Research Centre (CRC)/Transregio (TRR) which aims at employing regulatory T cells to create the basis for tailor-made immunotherapies. This initiative is an alliance of the University Mainz and…

read more

Carolin Daniel New Head of Research Unit ‘Type 1 Diabetes Immunology’

Since October 2022, Carolin Daniel heads the new, independent Helmholtz Munich Research Unit ‘Type 1 Diabetes Immunology’ (TDI). Her research, for which she already received numerous awards, focuses on the immunology of diabetes. We talked to her…

read more

Who We Are

Dr. Isabelle Serr

Deputy Department Head

Dr. Maike Becker

Postdoc

Dr. Martin Scherm

Postdoc

Dr. Alexey Surnov

Postdoc

Daria Opaleva

Postdoc

Hannah Hipp

Postdoc

Laura Harrison

Scientific Coordinator

Anne-Katrin Pelak

Team Assistant

Franziska Schadl

Biology Lab Technician

Anne Helena Neubig

Doctoral Researcher

Till Johannsmann

Doctoral Researcher

Gianmarco Spata

Doctoral Researcher

Jana Rohde

Doctoral Researcher

Sandra Maria Dirschl

Doctoral Researcher

Emily Schardey

Doctoral Researcher

Anne-Marie Bührer

Doctoral Researcher

Michael Lauber

Scientist

Franc Hysenaj

Medical Doctoral Researcher

Aina Bonet

Scientific Coordinator

TDI Publications | Key Publications

More on PubMed

2017 Cell Metabolism

Kälin S, Becker M, Ott VB, Serr I, Hosp F, Mollah MMH, Keipert S, Lamp D, Rohner-Jeanrenaud F, Flynn VK, Scherm MG, Nascimento LFR, Gerlach K, Popp V, Dietzen S, Bopp T, Krishnamurthy P, Kaplan MH, Serrano M, Woods SC, Tripal P, Palmisano R, Jastroch M, Bluher M, Wolfrum C, Weigmann B, Ziegler AG, Mann M, Tschöp MH, Daniel C.

A Stat6/Pten Axis Links Regulatory T Cells with Adipose Tissue Function

TDI Publications | Reviews

More on PubMed

Networks and Affiliations

Ludwig-Maximilians-Universität München

Technische Universität München

Helmholtz Munich Immunology

LMU - Clinical Pharmacology

SFB 1054

TRR 355

DZD

Contact Us

Laura Harrison

Scientific Coordinator

Type 1 Diabetes Immunology (TDI) Helmholtz Diabetes Center (HDC) Heidemannstraße 1 80939 Munich